120 related articles for article (PubMed ID: 21403462)
1. [A case of aggressive multiple myeloma].
Oda Y; Ooi S; Endoh A; Urushidani Y; Nakamura R; Adachi K
Gan To Kagaku Ryoho; 2011 Mar; 38(3):489-92. PubMed ID: 21403462
[TBL] [Abstract][Full Text] [Related]
2. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
3. [Multiple myeloma of the IgD-lambda type invading CNS].
Kitamura K; Takeuchi J; Kanbe E; Oka H; Saiki M; Aikawa S; Kura Y; Hatta Y; Yamazaki T; Ito T; Sawada U; Horie T
Rinsho Ketsueki; 2004 Oct; 45(10):1124-8. PubMed ID: 15553049
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib therapy following first relapse.
Orlowski RZ;
Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
[No Abstract] [Full Text] [Related]
5. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
Moriuchi M; Ohmachi K; Kojima M; Tsuboi K; Ogawa Y; Nakamura N; Ando K
Tokai J Exp Clin Med; 2010 Apr; 35(1):17-20. PubMed ID: 21319020
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
Kaposztas Z; Kahan BD; Katz SM; Van Buren CT; Cherem L
Transplant Proc; 2009 Dec; 41(10):4407-10. PubMed ID: 20005409
[TBL] [Abstract][Full Text] [Related]
7. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].
Mitina TA; Golenkov AK; Kataeva EV; Lutskaia TD; Trifonova EV; Klinushkina EF
Ter Arkh; 2010; 82(7):57-61. PubMed ID: 20853611
[TBL] [Abstract][Full Text] [Related]
10. [Nonproducing myeloma without evident bone lesion].
Kawatani T; Maeda N; Hosoda A; Agou H; Nakai K; Kawasaki H
Rinsho Ketsueki; 1990 Jun; 31(6):842-6. PubMed ID: 2214175
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).
Eom HS; Kim YK; Chung JS; Kim K; Kim HJ; Kim HY; Jin JY; Do YR; Oh SJ; Suh C; Seong CM; Kim CS; Lee DS; Lee JH
Ann Hematol; 2010 May; 89(5):489-97. PubMed ID: 20012045
[TBL] [Abstract][Full Text] [Related]
13. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
Ikeda H; Hayashi T; Nojima M; Yasui H; Ikeda Y; Ishida T; Adachi M; Imai K
Rinsho Ketsueki; 2005 Apr; 46(4):269-73. PubMed ID: 16444959
[TBL] [Abstract][Full Text] [Related]
14. [Plasmocytic pleural effusion disclosing multiple myeloma].
Elloumi M; Frikha M; Masmoudi H; Mseddi S; Ben Ayed M; Bouaziz M; Makni F; Souissi T
Rev Mal Respir; 2000 Apr; 17(2):495-7. PubMed ID: 10859769
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
[TBL] [Abstract][Full Text] [Related]
16. [Complete remission in multiple myeloma with natural interferon-alpha (HLBI) and melphalan/prednisolone intermittent therapy].
Ito M; Nakagawa T; Imoto S; Isobe T; Nakao Y
Rinsho Ketsueki; 1990 Jun; 31(6):847-52. PubMed ID: 2214176
[TBL] [Abstract][Full Text] [Related]
17. [Rapid growth of glioblastoma during therapy for multiple myeloma: case report].
Sonoda Y; Kumabe T; Umezawa K; Shimizu H; Murakawa Y; Kanamaru R; Yoshimoto T
No Shinkei Geka; 1998 Aug; 26(8):737-41. PubMed ID: 9744004
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma with multiple and bulky extramedullary plasmacytomas as initial presentation.
SAWADA T; NAJIMA Y; OHASHI K; KATO I; MIYAZAWA M; NAKANO M; KOBAYASHI T; YAMASHITA T; AKIYAMA H; SAKAMAKI H
Rinsho Ketsueki; 2009 Nov; 50(11):1635-40. PubMed ID: 20009440
[TBL] [Abstract][Full Text] [Related]
19. [Velcade in multiple myeloma].
Votiakova OM; Osmanov DSh; Demina EA; Falaleeva NA; Bialik TE; Riabukhina IuE; Timofeeva OL; Gromova EG; Kupryshina NA; Kochergina NV
Ter Arkh; 2007; 79(7):70-3. PubMed ID: 17802795
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
